Financing opportunities from China: targeting investors and shaping deals

Join us for the second meeting of the China SIG, where we will gain practical advice around obtaining investment from China, and hear some shared experiences from those who have done it before.

The China Biotech SIG has been set up with the China-Britain Business Council (CBBC), and supported by the Department for International Trade (DIT), to provide a discussion platform for BIA and CBBC members in the Biotech sector, exploring the opportunities for business growth in and with China, via trade and investment.

The group is open to BIA and CBBC members only. The event is free of charge, however please register as there is limited capacity.


Dr Jonathan Tobin

Dr Jonathan Tobin

Investment Director, Arix Bioscience

Tim Watson

Tim Watson

Associate Partner, Life Sciences, Instinctif Partners

Neil Clark

Neil Clark

Chief Executive Officer, Destiny Pharma

Joyce Xie

Joyce Xie

Director, IP Group

Wednesday 2 May 2018

Arnold and Porter
International Financial Centre
25 Old Broad St


15.00    Registration

15.30    Introduction


Lincoln Tsang, Arnold and Porter

Practical advice around investment from China

15.40    China Capital Market and the Chinese perspective

                Joyce Xie, IP Capital, IP Group

15.55    How to send the right message in China

                 Tim Watson, Associate Partner, Instinctif Partners

Lessons learned from deals made

16.10    Strategic agreements and collaboration

                Jonathan Tobin, Investment Director, Arix Bioscience

16.25    Chinese investment for drug development

                Neil Clark, CEO, Destiny Pharma

Discussion and Q&A

16.40    Q&A with all the speakers

17.00    Drinks and networking

18.00    Finish


BIA Annual Supporters